Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. APEIRON is a private biopharmaceutical company based in Vienna, Austria. The company co-developed QARZIBA for the treatment of high-risk neuroblastoma in patients aged 12 months and above.
Read the full article: Ligand to Acquire APEIRON Biologics AG for $100M //
Source: https://www.businesswire.com/news/home/20240706652097/en/%C2%A0Ligand-to-Acquire-APEIRON-Biologics-AG-for-100-Million